Disease Landscape and Forecast Insights

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing…

Facing a dramatic rise in expenditures for cancer therapies, U.S. healthcare payers are increasingly assessing the value of drugs relative to their prices, taking into account attributes such as…

The treatment of breast cancer requires a multidisciplinary approach incorporating surgery, radiotherapy, hormonal agents, targeted therapies, and chemotherapy. Treatment decisions are influenced…

The HER2-positive breast cancer treatment paradigm has undergone considerable change in recent years and is expected to evolve further as more novel therapies enter the market. The enthusiastic…

The treatment of breast cancer has a rich and diverse product pipeline and continues to be one of the most lucrative and active areas of research in oncology. However, the barriers to entry are…

Breast cancer affects thousands of individuals in Brazil and Mexico, and is managed with premium-priced agents, chemotherapy, and hormone therapy. In Mexico, coverage of treatment varies across the…

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis…

There are limited treatment options for patients with advanced/metastatic, triple-negative breast cancer because commonly used treatments in other breast cancer segments (i.e., hormonal therapies…

The treatment of breast cancer has a rich and diverse product pipeline and continues to be one of the most lucrative and active areas of research in oncology. However, the barriers to entry are…

Breast cancer requires a multidisciplinary treatment approach that incorporates surgery, radiotherapy, chemotherapies, and targeted therapies. Treatment decisions are influenced by disease stage,…

Biomarker-driven prescribing plays an increasingly prominent role in key oncology indications. The choice of therapy for breast cancer has long been informed by the presence of key biomarkers, and…

LaunchTrends: Ibrance (Wave 3) is the third in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched breast cancer…